stock.name

Astrazeneca plc - ADR

AZN

Market Cap$205.22B
Close$

Compare Astrazeneca plc - ADR

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Astrazeneca plc - ADRAstrazeneca plc - ADR34.52.17%15%4.80.7
marketMarket Avg59.61.27%31%6.41
HealthcareHealthcare Avg62.31.27%15%7.30.9

Earnings Call Q4 2023

February 8, 2024 - AI Summary

AstraZeneca achieved its goal of reaching $45 billion in sales by 2023, exceeding expectations.
The company expects low double-digit to low teens percentage growth in total revenue for 2024, driven by strong product sales and collaboration revenues.
Product sales are expected to continue growing strongly, with momentum from current products and new launches.

Exclusive for Stockcircle Pro members

Sign upSign Up
$68.67

Current Fair Value

1.4% upside

Undervalued by 1.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$205.22 Billion
Enterprise Value$227.88 Billion
Dividend Yield$1.436 (2.17%)
Earnings per Share$1.91
Beta0.54
Outstanding Shares3,100,411,036
Avg 30 Day Volume5,095,984

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio34.46
PEG507.31
Price to Sales4.84
Price to Book Ratio5.65
Enterprise Value to Revenue4.97
Enterprise Value to EBIT32.8
Enterprise Value to Net Income38
Total Debt to Enterprise0.13
Debt to Equity0.73

Revenue Sources

No data

ESG Score

No data

About AstraZeneca Plc

CEO: Pascal Soriot

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...